Palladone-Sr (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride, the active ingredient in Palladone-Sr, is an opioid analgesic presented as a solid oral dosage form for systemic use. It is employed to manage moderate to severe pain, particularly in patients who require continuous, around-the-clock opioid therapy.

GNH USA supplies Palladone-Sr as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Hydromorphone hydrochloride is an opioid analgesic that acts on the central nervous system to relieve pain. - Acute postoperative pain: Provides effective relief when rapid onset analgesia is required. - Cancer-related pain: Helps control persistent pain associated with malignant disease. - Severe chronic pain: Used when other analgesics are insufficient for long‑term pain management.

Hydromorphone may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Constipation: Reduced gastrointestinal motility leading to hard stools. - Nausea: Sensation of queasy stomach, often accompanied by vomiting. - Drowsiness: Sedation or feeling unusually sleepy. - Dry mouth: Decreased salivary flow causing oral dryness. - Dizziness: Light‑headed sensation, especially when standing quickly. - Pruritus: Itching without rash, often localized.

Serious or Rare Side Effects: - Respiratory depression: Markedly slowed breathing that can be fatal. - Severe hypotension: Dangerous drop in blood pressure. - Convulsions: Seizure activity in susceptible individuals. - Anaphylaxis: Acute allergic reaction with airway compromise. - adrenal insufficiency: Hormonal deficiency affecting stress response. - Cardiac arrhythmias: Abnormal heart rhythms that may require urgent care.

When prescribing Hydromorphone hydrochloride, clinicians should evaluate patient history and monitor for safety concerns. - Assess tolerance: Determine prior opioid exposure to guide dosing. - Monitor respiratory function: Watch for signs of slowed breathing, especially after initiation. - Evaluate renal and hepatic function: Adjust use in patients with impaired metabolism or excretion. - Avoid concurrent CNS depressants: Limit use with alcohol, benzodiazepines, or other sedatives. - Educate on dependence risk: Inform patients about potential for addiction and withdrawal. - Store below 25°C: keep in the original pack, protect from moisture.

Hydromorhydro  

---

---  

   t  t